 |
인쇄하기
취소
|
Novartis to launch Stalevo, anti-parkinson drug.
Novartis Korea launched Stalevo a combined anti-parkinson drug with levo-dopa/carbidopa/entacapone,, on May 2.
The company said that 50% of the patients who treated with Levo-dopa, which was developed in 1960s for the treatment of Parkinsonian disease experienced with a diminished therapeutic effect, and 15 to 20% of patients revealed a severe diminished effect but Carbidopa in Stalevo reduc...
The company said that 50% of the patients who treated with Levo-dopa, which was developed in 1960s for the treatment of Parkinsonian disease experienced with a diminished therapeutic effect, and 15 to 20% of patients revealed a severe diminished effect but Carbidopa in Stalevo reduc...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.